Table 1 Clinical characteristics, severity of IPF, and treatments in all patients with AE-IPF.
n = 39 episodes, median (range) | |
|---|---|
Age, years | 69 (50, 84) |
Sex, male/female | 37/2 |
Smoking, never/ex/current | 3/32/4 |
Smoking pack years at first AE | 35 (0, 80) |
Period from IPF-diagnosis to AE, mo | 75 (0, 205) |
Observation period, mo | 62 (2, 205)* |
The number of AEs, 1/2 | 32/7 |
BMI | 21.9 (16.3, 28.9) |
Body surface area, m2 | 1.59 (1.38, 1.91) |
Peripheral blood WBC at AE, /μL | 9755 (1900, 20000) |
Peripheral blood neutrophils at AE, /μL | 6954 (1539, 18200) |
CRP at AE, mg/dL | 7.4 (0.9, 23.7) |
Serum LDH at AE, IU/L | 347 (183, 693) |
Serum KL-6 at AE, U/mL | 1535 (481, 6404) |
Serum SP-D at AE, ng/mL | 338 (23, 1330) |
P/F ratio at AE | 176 (38, 386) |
HRCT extent scores at AE (full score: 25) | 21 (13, 25) |
Period from admission to the beginning of AE treatment, days | 1 (0, 17) |
Administration of steroid pulse therapy at AE, +/− | 40/0 |
Administration of Immunosuppressants at AE, +/− | 28/11 |
Data before AE** | |
FVC, % pred | 57.6 (37.5, 89.3) |
DLCO, % pred | 57.1 (33.5, 85.9) |
PaO2 at rest, Torr | 72.8 (49.0, 91.0) |
HRCT extent scores (full score: 25) | 12.5 (7, 19) |
Distance in 6MWT, mo | 370 (160, 507) |
Minimum SpO2 in 6MWT, % | 82 (60, 95) |
JRS severity grade of interstitial pneumonia, I/II/III/IV/unknown | 9/0/12/14/4 |
The GAP staging system, I/II/III/unknown | 7/13/14/5 |
Preceding treatments for IPF, +/− | 24/15 |
Preceding oxygen therapy, +/− | 13/26 |
